Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
BOT enters the week in a curious position: short sellers have quietly reduced their footprint over the past month, yet borrowing costs remain high and the company's most recent insider action was a near-$10 million open-market purchase.
The most striking data point for Robostrategy is the insider trade filed in July. President Andrew Kai Kang bought 272,405 shares at $36.71 on July 14, committing just under $10 million with no 10b5-1 plan in place. That is a discretionary bet at a price well above where the stock trades today at $27.69, meaning the position is currently underwater by roughly 25%. The April cluster adds context: Kang, COO Marc Weinstein, and affiliated entity FP Strategies all bought at $10.00 per share in April, and a director bought 400,000 shares at the same price in November 2025. The pattern across three separate events points to sustained conviction from those closest to the company, even as the stock has pulled back from its post-IPO highs.
Short positioning tells a more restrained story, though the borrow market remains charged. The ORTEX short score has held in a tight band between 68 and 70 for the past two weeks, ending the period at 69.1. That level is elevated but not extreme. Short shares outstanding have slipped roughly 15% over the past month, from around 1.42 million in late August to 1.19 million now, a meaningful reduction in the bearish book. The float percentage of short interest cannot be computed from the available data, so the absolute level is hard to contextualise. What is clear is that borrowing costs, while easing, are still high at 28.2%, down from a peak near 49.5% in early September. That drop of more than 40% in borrowing costs over 30 days reflects shorts becoming easier to establish, which may partly explain why some earlier positions were covered. Availability has loosened materially too, climbing from a 52-week low of 12.5% to 155.7% now, meaning there is roughly one and a half shares available to borrow for every one already lent out. The lending market is no longer under the stress it was in early September.
Options positioning has shifted notably less bearish in recent days. The put/call ratio dropped to 1.04 this week, running nearly 1.6 standard deviations below its 20-day average of 1.17. That average itself is tilted defensively, with puts outnumbering calls throughout September and into early October. The recent slide in the PCR suggests some of that hedging demand has come off, possibly alongside the short covering visible in the SI data. The 52-week PCR high of 1.56 gives the current reading room to move in either direction.
With no analyst coverage, no valuation multiples, no earnings history and no institutional holders on record, Robostrategy is a thin data environment. The alt data layer covers only the insider cluster dataset from SEC EDGAR, and no measured leading indicators are available for the company's own financials. What exists is essentially the insider register, the borrow market, and price. The stock is down 5.6% on the week and has given back much of the gains from a month ago despite being up 1.8% over that horizon.
What to watch next: whether the borrow cost continues its downward path toward more normal territory, and whether any additional insider filings emerge to reinforce or complicate the conviction signalled by the July purchase.
See the live data behind this article on ORTEX.
Open BOT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
